Ligand-Controlled Reactivity and Cytotoxicity of Cyclometalated Rhodium(III) Complexes

Overview

Journal Eur J Inorg Chem

Date 2021 Mar 29

PMID 33776557

Citations 5

Authors

Wen-Ying Zhang

Hannah E Bridgewater

Samya Banerjee

Joan J Soldevila-Barreda

Guy J Clarkson

Huayun Shi

Cinzia Imberti

Peter J Sadler

Affiliations

Soon will be listed here.

Abstract

We report the synthesis, characterisation and cytotoxicity of six cyclometalated rhodium(III) complexes [CpRh(C^N)Z], in which Cp = Cp*, Cp, or Cp, C^N = benzo[h]quinoline, and Z = chloride or pyridine. Three x-ray crystal structures showing the expected "piano-stool" configurations have been determined. The chlorido complexes hydrolysed faster in aqueous solution, also reacted preferentially with 9-ethyl guanine or glutathione compared to their pyridine analogues. The 1-biphenyl-2,3,4,5,-tetramethylcyclopentadienyl complex [CpRh(benzo[h]quinoline)Cl] () was the most efficient catalyst in coenzyme reduced nicotinamide adenine dinucleotide (NADH) oxidation to NAD and induced an elevated level of reactive oxygen species (ROS) in A549 human lung cancer cells. The pyridine complex [CpRh(benzo[h]quinoline)py] () was the most potent against A549 lung and A2780 ovarian cancer cell lines, being 5-fold more active than cisplatin towards A549 cells, and acted as a ROS scavenger. This work highlights a ligand-controlled strategy to modulate the reactivity and cytotoxicity of cyclometalated rhodium anticancer complexes.

Citing Articles

Half-Sandwich Rhodium Complexes with Releasable N-Donor Monodentate Ligands: Solution Chemical Properties and the Possibility for Acidosis Activation.

Meszaros J, Kandioller W, Spengler G, Prado-Roller A, Keppler B, Enyedy E Pharmaceutics. 2023; 15(2).

PMID: 36839678 PMC: 9964319. DOI: 10.3390/pharmaceutics15020356.

Systematic Study on the Cytotoxic Potency of Commonly Used Dimeric Metal Precursors in Human Cancer Cell Lines.

Geisler H, Harringer S, Wenisch D, Urban R, Jakupec M, Kandioller W ChemistryOpen. 2022; 11(7):e202200019.

PMID: 35212190 PMC: 9278098. DOI: 10.1002/open.202200019.

Transfer hydrogenation catalysis in cells.

Banerjee S, Sadler P RSC Chem Biol. 2021; 2(1):12-29.

PMID: 34458774 PMC: 8341873. DOI: 10.1039/d0cb00150c.

Metallodrugs are unique: opportunities and challenges of discovery and development.

Anthony E, Bolitho E, Bridgewater H, Carter O, Donnelly J, Imberti C Chem Sci. 2021; 11(48):12888-12917.

PMID: 34123239 PMC: 8163330. DOI: 10.1039/d0sc04082g.

Synthesis, Characterisation and In Vitro Anticancer Activity of Catalytically Active Indole-Based Half-Sandwich Complexes.

Soldevila-Barreda J, Fawibe K, Azmanova M, Rafols L, Pitto-Barry A, Eke U Molecules. 2020; 25(19).

PMID: 33022980 PMC: 7583056. DOI: 10.3390/molecules25194540.

References

Novohradsky V, Liu Z, Vojtiskova M, Sadler P, Brabec V, Kasparkova J . Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand. Metallomics. 2014; 6(3):682-90. DOI: 10.1039/c3mt00341h. View

Gasser G, Ott I, Metzler-Nolte N . Organometallic anticancer compounds. J Med Chem. 2010; 54(1):3-25. PMC: 3018145. DOI: 10.1021/jm100020w. View

Yang G, Wang W, Mok S, Wu C, Law B, Miao X . Selective Inhibition of Lysine-Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple-Negative Breast Cancer Therapy. Angew Chem Int Ed Engl. 2018; 57(40):13091-13095. DOI: 10.1002/anie.201807305. View

Su W, Luo Z, Dong S, Chen X, Xiao J, Peng B . Novel half-sandwich rhodium(III) and iridium(III) photosensitizers for dual chemo- and photodynamic therapy. Photodiagnosis Photodyn Ther. 2019; 26:448-454. DOI: 10.1016/j.pdpdt.2019.04.028. View

Gupta G, Kumari P, Ryu J, Lee J, Mobin S, Lee C . Mitochondrial Localization of Highly Fluorescent and Photostable BODIPY-Based Ruthenium(II), Rhodium(III), and Iridium(III) Metal Complexes. Inorg Chem. 2019; 58(13):8587-8595. DOI: 10.1021/acs.inorgchem.9b00898. View

Liu Z, Salassa L, Habtemariam A, Pizarro A, Clarkson G, Sadler P . Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes. Inorg Chem. 2011; 50(12):5777-83. DOI: 10.1021/ic200607j. View

Kastl A, Wilbuer A, Merkel A, Feng L, Di Fazio P, Ocker M . Dual anticancer activity in a single compound: visible-light-induced apoptosis by an antiangiogenic iridium complex. Chem Commun (Camb). 2011; 48(13):1863-5. DOI: 10.1039/c1cc15378a. View

Vichai V, Kirtikara K . Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2007; 1(3):1112-6. DOI: 10.1038/nprot.2006.179. View

Soldevila-Barreda J, Habtemariam A, Romero-Canelon I, Sadler P . Half-sandwich rhodium(III) transfer hydrogenation catalysts: Reduction of NAD(+) and pyruvate, and antiproliferative activity. J Inorg Biochem. 2015; 153:322-333. DOI: 10.1016/j.jinorgbio.2015.10.008. View

10.

Meszaros J, Poljarevic J, Gal G, May N, Spengler G, Enyedy E . Comparative solution and structural studies of half-sandwich rhodium and ruthenium complexes bearing curcumin and acetylacetone. J Inorg Biochem. 2019; 195:91-100. DOI: 10.1016/j.jinorgbio.2019.02.015. View

11.

Wilbuer A, Vlecken D, Schmitz D, Kraling K, Harms K, Bagowski C . Iridium complex with antiangiogenic properties. Angew Chem Int Ed Engl. 2010; 49(22):3839-42. DOI: 10.1002/anie.201000682. View

12.

Stringer T, Melis D, Smith G . N,O-Chelating quinoline-based half-sandwich organorhodium and -iridium complexes: synthesis, antiplasmodial activity and preliminary evaluation as transfer hydrogenation catalysts for the reduction of NAD. Dalton Trans. 2019; 48(35):13143-13148. DOI: 10.1039/c9dt02030f. View

13.

Gilewska A, Barszcz B, Masternak J, Kazimierczuk K, Sitkowski J, Wietrzyk J . Similarities and differences in d low-spin ruthenium, rhodium and iridium half-sandwich complexes: synthesis, structure, cytotoxicity and interaction with biological targets. J Biol Inorg Chem. 2019; 24(4):591-606. PMC: 6598960. DOI: 10.1007/s00775-019-01665-2. View

14.

Fisher D . Apoptosis in cancer therapy: crossing the threshold. Cell. 1994; 78(4):539-42. DOI: 10.1016/0092-8674(94)90518-5. View

15.

Ma D, Liu L, Leung K, Chen Y, Zhong H, Chan D . Antagonizing STAT3 dimerization with a rhodium(III) complex. Angew Chem Int Ed Engl. 2014; 53(35):9178-82. DOI: 10.1002/anie.201404686. View

16.

Ma D, Wang M, Mao Z, Yang C, Ng C, Leung C . Rhodium complexes as therapeutic agents. Dalton Trans. 2016; 45(7):2762-71. DOI: 10.1039/c5dt04338g. View

17.

Liu Z, Sadler P . Organoiridium complexes: anticancer agents and catalysts. Acc Chem Res. 2014; 47(4):1174-85. PMC: 3994614. DOI: 10.1021/ar400266c. View

18.

Shah N, Dizon D . New-generation platinum agents for solid tumors. Future Oncol. 2009; 5(1):33-42. DOI: 10.2217/14796694.5.1.33. View

19.

Zhang D, Zheng Y, Zhang H, Sun J, Tan C, He L . Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal-Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging. Adv Sci (Weinh). 2018; 5(10):1800581. PMC: 6193176. DOI: 10.1002/advs.201800581. View

20.

Hanif M, Hartinger C . Anticancer metallodrugs: where is the next cisplatin?. Future Med Chem. 2018; 10(6):615-617. DOI: 10.4155/fmc-2017-0317. View